Utilizing complement inhibition in IgA nephropathy
Nephrology · 2024
DOI: 10.1111/nep.14347 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology, 2024. Verfasst von Richard Lafayette. Beteiligte Einrichtung: Stanford Glomerular Disease Center, Stanford University Medical Center, Stanford, California, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Complement Inactivating Agents, Complement Activation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
The role of complement in the pathogenesis of IgA nephropathy has been heavily explored over the past 50 years. This has led to the general acceptance that complement plays an important role in the clinical presentation and risk for progression of disease in patients with IgA nephropathy. Herein, we review the evidence for complement activation in IgA nephropathy, focusing on evidence that the lectin and alternate pathways are the main actors. We are entering an era of intense investigation of various inhibitors of complement, which should ultimately be the best indicator of contributions of the lectin, alternate and common complement pathways to disease burden. More importantly, we will see if these efforts result in the discovery of clinically relevant options in managing this important disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stanford Glomerular Disease Center, Stanford University Medical Center, Stanford, California, USA.
ORCID-Profile: Richard Lafayette
Zitieren
APA
Lafayette, R. (2024). Utilizing complement inhibition in IgA nephropathy. Nephrology. https://doi.org/10.1111/nep.14347
Vancouver
Lafayette R. Utilizing complement inhibition in IgA nephropathy. Nephrology. 2024. doi:10.1111/nep.14347
BibTeX
@article{Lafayette2024,
author = {Lafayette, Richard},
title = {Utilizing complement inhibition in IgA nephropathy},
journal = {Nephrology},
year = {2024},
doi = {10.1111/nep.14347}
}
EUVIMED